Meningococcal disease kills 10 to 15 percent of the people it infects, even when antibiotics start within hours. Another 10 to 20 percent of survivors lose limbs, hearing, or cognitive function. CDC counts roughly 350 cases per year in the United States, a small number that hides how fast individual cases collapse: a college student with a headache at noon can be septic by midnight.
The bacterium is preventable. Two separate vaccine families cover the five serogroups responsible for almost all human disease. The trouble is that almost no adult remembers their teenage immunization records, college outbreak clusters keep recurring, and the MenB vaccine still gets prescribed inconsistently. This guide is the part of infection prevention that hinges on getting the right vaccine at the right age, then knowing the warning signs cold.
Key Takeaways
- The pentavalent MenABCWY vaccine (Penbraya, approved 2023) now covers serogroups A, B, C, W, and Y in a single shot for adolescents 10 to 25.
- Routine US schedule: MenACWY at age 11 or 12, booster at 16. MenB shared-decision at 16 to 23. CDC added MenABCWY as an option for the 16-year-old dose in 2024.
- Meningococcal disease can kill within 24 hours of first symptoms. Petechial rash, neck stiffness, and altered mental status mean call an ambulance, not the GP.
- College freshmen living in dorms have a higher carriage rate and outbreak risk. Many universities require MenACWY proof; MenB is recommended but rarely required.
- Saudi Arabia mandates MenACWY for Hajj and Umrah pilgrims after the global W135 outbreak that began at Hajj 2000. The certificate must be at least 10 days old and not more than 3 years old at entry.
What is meningococcal disease?
Meningococcal disease is any infection caused by Neisseria meningitidis, a bacterium that lives in the nose and throat of about 10 percent of healthy adults. It becomes invasive when it crosses into the bloodstream or the cerebrospinal fluid, producing meningitis (brain and spinal cord lining infection) or meningococcemia (bloodstream infection with sepsis).
Six serogroups cause nearly all human disease: A, B, C, W, X, and Y. Vaccines exist for five of them. Serogroup X has no licensed vaccine and concentrates in the African meningitis belt. Globally, WHO estimates around 1.2 million cases and 135,000 deaths each year, with the highest incidence in sub-Saharan Africa during the December-to-June dry season.
Who is at highest risk?
Risk concentrates in five groups: infants under one year, adolescents and young adults aged 16 to 23, college freshmen in dorms, people with complement deficiencies (including those on the C5 inhibitors eculizumab and ravulizumab), and travelers to the African meningitis belt or to Hajj. The complement-inhibitor risk is large enough that CDC and FDA require the prescribing pharmacy to confirm vaccination before each infusion.
Age-specific rates from US CDC surveillance:
| Age group | Incidence per 100,000 | Notes |
|---|---|---|
| Under 1 year | 1.0 | Highest infant risk; serogroup B dominant |
| 1 to 10 years | 0.1 | Trough years |
| 11 to 24 years | 0.3 to 0.4 | Adolescent secondary peak |
| Over 65 years | 0.2 | Often serogroup Y |
Smoking, both active and passive, raises risk by promoting carriage. Crowded sleeping quarters (dorms, military barracks, prisons, Hajj tents) raise transmission. HIV and asplenia raise invasive risk once colonized.
How does meningococcal disease spread?
It spreads through respiratory droplets and direct contact with saliva, including kissing, shared cups and utensils, smoking the same cigarette, and prolonged close-quarters exposure. Casual contact in classrooms or workplaces almost never transmits. Carriage in the back of the throat is common and usually harmless; invasive disease is rare and unpredictable.
The incubation period runs 1 to 10 days, typically 3 to 4 days. Once carried, the bacterium can either clear on its own, persist as harmless colonization, or invade. Outbreaks happen when a virulent strain finds a population with low immunity, low vaccine coverage, and high carriage transmission, which is exactly the formula a freshman dorm produces.
What do MenACWY and MenB vaccines cover?
MenACWY vaccines protect against serogroups A, C, W, and Y. MenB vaccines protect only against serogroup B. The two vaccine families use different antigens (capsular polysaccharide conjugates for ACWY, recombinant proteins for B), and they are not interchangeable. You need both to cover the five vaccine-preventable serogroups in the US.
Currently licensed in the US:
- MenACWY: Menactra (discontinued 2024), Menveo, MenQuadfi
- MenB: Bexsero (2 doses), Trumenba (2 or 3 doses)
- MenABCWY (pentavalent): Penbraya (Pfizer, approved Oct 2023). One injection covers all five serogroups when given at the same visit a separate MenACWY and MenB would have been
Penbraya is the practical change for most adolescents. The 16-year-old booster dose can now be a single shot rather than two separate vaccines, and ACIP added it to the routine schedule in 2024. Vaccine efficacy for MenACWY runs 80 to 85 percent against vaccine-type disease in the first year and wanes meaningfully by year five, which is why the booster matters.
When should adults get a meningococcal booster?
Adults need a booster if they are at ongoing risk: complement inhibitor therapy, asplenia, microbiology lab work with N. meningitidis, military recruits, travelers to the African meningitis belt or Hajj, and people in outbreak settings. CDC recommends MenACWY revaccination every 5 years for ongoing risk, and MenB every 2 to 3 years on the same indication.
If you got the routine adolescent series, finished college, and have no ongoing risk factor, you are not due for a booster. If you cannot remember whether you got the 16-year-old booster, ask your pediatrician's office for the immunization record before assuming you are protected. Travel medicine clinics will check this routinely; primary care often will not.
How do you recognize meningococcal symptoms in time?
The first 6 to 12 hours of meningococcal sepsis can look like flu: fever, headache, fatigue, muscle ache. The symptoms that should send you to an emergency department immediately are neck stiffness, photophobia, altered mental status, leg pain or cold extremities out of proportion to the fever, and a non-blanching rash (petechiae or purpura that does not fade when pressed under a glass).
A rapid clinical decision rule used in UK emergency medicine: a child or young adult with fever plus any one of (1) cold hands and feet, (2) leg pain, (3) abnormal skin color is treated as suspected meningococcal sepsis until proven otherwise. Antibiotics go in within an hour. The classic triad of fever, neck stiffness, and altered mental status appears in only about 40 percent of confirmed meningitis cases at presentation, so waiting for it is dangerous.
FAQ
Do I still need the MenB vaccine if I got Penbraya?
Penbraya already includes the MenB component, so a separate MenB series is not needed if you completed Penbraya. If you got an older MenACWY-only vaccine and never had MenB, ACIP says talk to your clinician about a MenB series, especially if you are 16 to 23 years old or have a risk factor.
Why do colleges require MenACWY but not MenB?
State immunization laws were written before MenB vaccines existed, and most have not been updated. MenB outbreaks at US universities (Princeton 2013, UC Santa Barbara 2013, Oregon State 2016, UMass Amherst 2024) typically trigger campus-wide MenB campaigns rather than statewide mandates. The protection gap is real and a known vaccine efficacy issue.
What antibiotic prevents meningococcal disease after exposure?
Close contacts (household members, kissing partners, anyone sharing a sleeping space, healthcare workers with mouth-to-mouth resuscitation exposure) get prophylaxis with ciprofloxacin (single 500 mg dose for adults), rifampin (4 doses over 2 days), or ceftriaxone (single IM injection). Casual contacts do not need prophylaxis.
Can a healthy adult catch meningococcal disease from a carrier?
Yes, but it is rare. About 10 percent of adults carry N. meningitidis asymptomatically; only a tiny fraction of carriers transmit, and only a tiny fraction of those who acquire the bacterium develop invasive disease. The risk is concentrated in people with complement deficiencies, asplenia, or recent viral upper respiratory infections that disrupt mucosal defenses.
Is there a meningococcal vaccine required for international travel?
Saudi Arabia requires a current MenACWY certificate for all Hajj and Umrah pilgrims aged 2 and older. Travel to the African meningitis belt (a band from Senegal to Ethiopia) is a vaccine indication during the December-to-June dry season. Most other destinations do not require it but may recommend it depending on age and itinerary.